

1 **Mild SARS-CoV-2 infection modifies DNA methylation of peripheral blood**
2 **mononuclear cells from COVID-19 convalescents**

3 Johanna Huoman, PhD^{1*}, Shumaila Sayyab, PhD^{1*}, Eirini Apostolou, PhD², Lovisa Karlsson,
4 MSc¹, Lucas Porcile¹, Muhammad Rizwan, MSc², Sumit Sharma, PhD³, Jyotirmoy Das,
5 PhD¹, Anders Rosén², PhD and Maria Lerm, PhD^{1**}

6 *Shared first authorship

7 **Corresponding author

8

9 ¹Division of Inflammation and Infection, Department of Biomedical and Clinical Sciences,
10 Linköping University, Linköping, Sweden

11 ²Division of Cell Biology, Department of Biomedical and Clinical Sciences, Linköping
12 University, Linköping, Sweden

13 ³Division of Molecular Medicine and Virology, Department of Biomedical and Clinical
14 Sciences, Linköping University, Linköping, Sweden

15

16 Corresponding author:

17 Maria Lerm, PhD, Professor

18 Department of Biomedical and Clinical Sciences

19 Division of Inflammation and Infection, Lab1, floor 12

20 Faculty of Medicine and Health Sciences

21 SE-581 85 Linköping, Sweden

22 Cell phone: +46-73-2707786

23 Visit us at: <https://liu.se/en/employee/marle69>

24 **ABSTRACT**

25 **Background:** Coronaviruses such as SARS-CoV-2 may circumvent host defence
26 mechanisms by hijacking host proteins, possibly by altering DNA methylation patterns in host
27 cells. While most epigenetic studies have been performed in severely ill COVID-19 patients,
28 studies on individuals who have recovered from mild-to-moderate disease remain scarce.
29 The aim of this study was to assess epigenome-wide DNA methylation patterns in COVID-19
30 convalescents compared to uninfected controls from before and after the pandemic outbreak
31 began.

32 **Methods:** DNA was extracted from peripheral blood mononuclear cells originating from
33 uninfected controls before (Pre20, n=5) and after (Con, n=18) 2020, COVID-19
34 convalescents (CC19, n=14) and symptom-free individuals with a SARS-CoV-2-specific T
35 cell response (SFT, n=6), as well as from Pre20 (n=4) samples stimulated *in vitro* with
36 SARS-CoV-2. Subsequently, epigenome-wide DNA methylation analyses were performed
37 using the Illumina MethylationEPIC 850K array, and statistical and bioinformatic analyses
38 comprised differential DNA methylation, pathway over-representation and module
39 identification network analyses.

40 **Results:** DNA methylation patterns of COVID-19 convalescents were altered as compared to
41 uninfected controls, with similar results observed in *in vitro* stimulations of PBMC with SARS-
42 CoV-2. Differentially methylated genes from the *in vivo* comparison constituted the
43 foundation for the identification of a possibly SARS-CoV-2-induced module, containing 66
44 genes of which six could also be identified in corresponding analyses of the *in vitro* data
45 (TP53, INS, HSPA4, SP1, ESR1 and FAS). Pathway over-representation analyses revealed
46 involvement of Wnt, cadherin and apoptosis signalling pathways amongst others.
47 Furthermore, numerous interactions were found between the obtained differentially
48 methylated genes from both settings and the network analyses when overlaying the data
49 unto the SARS-CoV-2 interactome.

50 **Conclusions:** Epigenome-wide DNA methylation patterns of individuals that have recovered
51 from mild-to-moderate COVID-19 are different from those of non-infected controls. The
52 observed alterations during both *in vivo* and *in vitro* exposure to SARS-CoV-2 showed
53 involvement in interactions and pathways that are highly relevant to COVID-19. The present
54 study provides indications that DNA methylation is one of several epigenetic mechanisms
55 that is altered upon SARS-CoV-2 infection. Further studies on the mechanistic underpinnings
56 should determine whether the observed effects are reflecting host-protective antiviral
57 defence or targeted viral hijacking to evade host defence.

58

59

60

61

62

63

64

65

66

67

68

69

70

71 **Keywords (max. 10 words):** COVID-19, DNA methylation, interactome, *in vitro* stimulation,
72 mild-to-moderate, module identification, network analysis, PBMC, SARS-CoV-2

73 **BACKGROUND**

74 Severe acute respiratory syndrome (SARS) caused by coronaviruses is not new to the world,
75 but at the emergence of the SARS coronavirus 2 (SARS-CoV-2) in December 2019, the
76 global community was largely unprepared. Despite the outbreak of SARS-CoV-1 in 2003,
77 very limited understanding of coronavirus biology and no vaccine portfolio was available at
78 the time of the SARS-CoV-2 outbreak in 2019. To understand SARS-CoV-2 biology, the
79 underlying mechanisms of how the virus interacts with its host needs to be scrutinized and
80 this knowledge is crucial for the development of effective treatment and prevention of
81 coronavirus disease 19 (COVID-19), the disease caused by the virus.

82 DNA methylation (DNAm) is the most stable epigenetic modification, as it ensures heritability
83 in the cell division process, but is at the same time highly dynamic in response to
84 environmental stimuli (1). The malleability and flexibility of the DNA methylome decreases
85 with increasing age (2), and environmental factors such as smoking and nutrition may alter
86 DNAm patterning in various cell types, including different immune cells (3). Epigenetic
87 changes in *i.a.* immune cell populations have been reported both in immune-related diseases
88 and allergies (4) as well as infectious diseases (5-7). In line with this, we have observed that
89 immune cells of asymptomatic, tuberculosis-exposed individuals carry a lasting DNAm
90 biosignature (8-10) that is linked to protection against mycobacterial infection (8). However,
91 epigenetic alterations can also be induced by pathogens for their own benefit (11-14).

92 A majority (40-80%) of individuals infected with SARS-CoV-2 show no or mild symptoms of
93 COVID-19 and proceed into convalescence thereafter, while a smaller, but non-negligible,
94 proportion of individuals show severe or life-threatening manifestations (15, 16). However,
95 thus far, no studies have addressed whether and how the epigenome is altered in subjects
96 with a recent mild-to-moderate SARS-CoV-2 infection. In this study, we set out to examine
97 epigenome-wide DNAm patterns in convalescent COVID-19 (CC19) subjects, after a mild-to-
98 moderate disease course. Understanding how convalescent COVID-19 individuals mount an
99 epigenetically encoded defence strategy against new viruses such as SARS-CoV-2, for

100 which no pre-existent immunity was present, may reveal how a functional defence towards
101 SARS-CoV-2 is mounted, and guide development of novel diagnostic and preventive
102 measures. Indeed, we could show that a number of genes that interact with SARS-CoV-2
103 interacting proteins were epigenetically modulated in these individuals, suggesting that
104 appropriate host defence may be initiated on a cellular level by altered DNAm patterning in
105 virus-exploited host proteins.

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121


122 **RESULTS**

123 **COVID-19 convalescents display altered DNAm patterns compared to non-infected**
 124 **controls**


125 As we were interested in studying DNAm as a defence mechanism in COVID-19, we
 126 compared epigenome-wide DNAm patterning in peripheral blood mononuclear cells (PBMC)
 127 from non-infected controls (Con, n=19), COVID-19 convalescents who had recovered from
 128 mild or

129 **Figure 1.**


Study participants



Experimental procedure



Statistics and bioinformatics




130 **Figure 1. Outline of included participants, experimental procedures as well as statistical and**
 131 **bioinformatic approaches utilised in the present study.** CC19 – convalescent COVID-19, Con –
 132 non-infected control, DMG – differentially methylated gene, Pre20 – Pre-2020 non-infected control,

133 SFT – symptom-free individuals with SARS-CoV-2-specific T cell response, SMIA – suspension
134 multiplex immunoassay.

135 moderate symptoms (CC19, n=14), donor blood collected before the pandemic (Pre20, n=5)
136 and from asymptomatic individuals presenting with SARS-CoV-2-specific T cell responses
137 (SFT, n=6, Figure 1). Comparisons of demographic variables revealed no significant
138 differences between any of the groups (Table S1). To examine any inherent differences in
139 the DNA methylome between the different sample groups, principal component analyses
140 (PCA) were performed. Three principal components (PC) were identified as both contributing
141 to the variation within the DNAm data and correlating with the sample groups (Figure 2A-B).
142 A three-dimensional illustration of these three most contributing components revealed that
143 the CC19 subjects are distinct from the Con, Pre20 and SFT subjects, whose centroids
144 cluster more


145 **Figure 2.**

146 **A.**



151

152 **B.**



153

154


155

156

157

158

159 **C.**



160 **Figure 2. PCA analysis of PBMC DNA methylomes.** Upon filtering and normalisation, the DNAm
161 data were subjected to PCA analysis. A. shows a correlation plot of the PCA-derived eigenvalues and
162 the DNAm group data projected as Con/Pre20/CC19/SFT and male/female. In B. a scree-plot shows
163 degree to which the identified components contribute to the variation observed within the DNAm data.
164 C. shows a 3D-PCA plot of principal component (PC)1, PC3 and PC5, where the group means are
165 illustrated as centroids.


166 **Figure 3.**

167 **A.**

168

169


170



171

172

173



174 **Figure 3. Identification of differentially methylated CpGs in CC19 subjects vs. uninfected**

175 **controls.** DMCs were identified comparing CC19s to Cons and Pre20s by computing a linear model

176 on the DNAm data. A. illustrates a volcano plot of the CC19 vs. Con + Pre20 DNAm data. The dash-

177 dotted horizontal line represents a nominal p-value cut-off of 0.01, and the vertical lines represent a

178 cut-off in mean methylation difference (MMD) in CC19 vs. Con + Pre20 of $> \pm 0.2$. B. shows a

179 heatmap representing an unsupervised hierarchical clustering analysis of individual β values of the 87

180 identified DMCs in A. The individuals' antibody status is indicated as a grey-scale (unknown in

181 anonymous Pre20 blood donors, orange).

182 closely together (Figure 2C, Figure S1). The observed methylome differences prompted us to

183 identify differentially methylated CpGs (DMCs), which we defined as CpG sites with a

184 nominal p-value of < 0.01 along with a mean methylation difference (MMD) of > 0.2 . We found

185 87 DMCs, 30 of which were hypomethylated and 57 DMCs were hypermethylated when

186 comparing the DNA methylomes of CC19s to the merged groups of Cons and Pre20s (Figure

187 3A, Table S2a). This identified DMC signature could furthermore accurately distinguish the

188 CC19s from Cons, Pre20s and SFTs (Figure 3B), suggesting that a past SARS-CoV-2

189 infection may have resulted in modulation of the epigenome that persists at least a couple of

190 months after the virus is eliminated from the body. Interestingly, a majority of CC19s showed
191 positive SARS-CoV-2-specific IgG responses both in the circulation and in saliva (Figure 3B).
192 The individuals who were positive for SARS-CoV-2-specific T cells or antibodies in saliva,
193 while being negative for antibodies in plasma, aligned with the controls in the PCA and
194 unsupervised clustering analyses (Figure 3A-B).

195

196 **Differentially methylated genes of COVID-19 convalescents identify a putatively SARS-** 197 **CoV-2-induced module**

198 To further explore the biological impact of SARS-CoV-2 exposure in the CC19 subjects, the
199 identified DMCs were annotated to their respective differentially methylated genes (DMG),
200 resulting in 54 unique genes, of which 18 genes were hypomethylated, 35 hypermethylated,
201 and one gene featured a mixed methylation pattern (Table S2b). Subsequent pathway over-
202 representation analyses using the identified DMGs from the CC19 to the combined Con and
203 Pre20 subject comparison revealed involvement in two significantly over-represented
204 pathways (Wnt and integrin signalling pathways, Table S3).

205 As a means to elaborate on the wider interaction context in which the DMGs act with other
206 proteins, the DMGs (n=54) were used as seed genes in the identification of SARS-CoV-2-
207 induced modules in network analyses. The resulting module consisted of 66 genes from the
208 protein-protein interaction (PPI) network, with 139 interactions, which is significantly more
209 interactions than the expected (34 interactions) for a network of that size (Figure 4A, Table
210 S4). Six of these genes were present in at least two module identification methods (*INS*,
211 *HSPA4*, *SP1*, *ESR1*, *TP53*, *FAS*), and they were all located in the centre of the module. The
212 four genes with the highest combined centrality scores were *HSP90AA1*, *TP53*, *INS* and
213 *CFTR*. Pathway over-representation analyses of the 66 module genes revealed involvement
214 in pathways such as apoptosis signalling, muscarinic acetylcholine receptor 1 and 3
215 signalling and gonadotropin-releasing hormone pathway (Figure 4B).

216

217 **Figure 4.**

218 **A.**

219

220

221

222

223

224


225

226

227

228

229



230 **B.**



231 **Figure 4. Network illustration and analysis of significantly differentiated methylated genes from**
232 **the *in vivo* setting.** A. shows the network module constructed by means of the graph clustering
233 algorithm MCODE with the 54 DMGs as input. Nodes (n=66) represent genes and connecting lines
234 represent high-confidence protein-protein interactions within the network (STRING combined score >
235 0.7). Combined ranked scores of centrality quantification of degree, betweenness and closeness is
236 visualised as a colour (light orange to dark red) continuum, with dark red nodes constituting the most
237 central parts of the network. Nodes that were also found both when utilising two other module
238 identifying methods (DIAMOnD and WGCNA) and when performing the same analyses on the *in vitro*
239 data set using MCODE are enclosed with a black line. B. displays results from pathway over-
240 representation analyses of the 66 identified network genes in the protein-protein interaction network
241 using PANTHER. Pathways with an FDR-corrected p-value < 0.05 were considered significant.


242 **PBMCs stimulated with SARS-CoV-2 *in vitro* reveal differential methylation in multiple**
243 **pathways important for the viral life cycle**

244 In the present study, we only had access to self-reported time-after-onset of COVID-19
245 symptoms (Table S5), thus making the immediate effects of SARS-CoV-2 exposure on the
246 epigenome impossible to analyse. Moreover, as the virus-induced DNAm patterns in the
247 CC19's may fade over time, we set out to examine the possible role of SARS-CoV-2-induced
248 DNAm patterns in host defence in an *in vitro* setting. To this end, we exposed PBMCs
249 collected from blood donors in 2019 to SARS-CoV-2 at a low multiplicity of infection for 48h
250 to mimic immediate *in vivo* exposure to the virus (Figure S2). Exploring the intraindividual
251 DNAm differences between stimulated and unstimulated cells, a set of DMCs (n=3693) were
252 identified to be shared between all four individuals, of which 1523 were hypermethylated
253 (Table S6a) and 2170 were hypomethylated (Table S6b). These DMCs mapped to in total
254 606 DMGs (542 unique genes, Table S6c), consisting of 215 hypermethylated and 391
255 hypomethylated genes (Figure 4A), which were significantly over-represented in a number of
256 pathways including several glutamate receptor pathways, muscarinic acetylcholine receptor
257 1 and 3 signalling pathway, as well as the Wnt and cadherin signalling pathways (Figure 4B).

258

259 **Figure 4.**

260 **A.**



261 **B.**

262

263

264

265

266

267


268

269

270

271

Figure



4.

272 **Differential DNAm analyses of PBMCs stimulated *in vitro* with SARS-CoV-2.** A. Venn diagrams
273 depicting the overlap of DMCs from the SARS-CoV-2 *in vitro* stimulated PBMCs. Intraindividual
274 comparisons of differential DNAm were performed in treated vs. untreated PBMCs from four different
275 blood donors (D1-D4) collected before the start of the COVID-19 pandemic (2014-2019). DMCs were
276 defined as a fold change in M-value $>|2|$. These DMCs were further mapped to their corresponding
277 annotated genes (DMGs, n=542). B shows results from pathway over-representation analyses in
278 PANTHER based on the 542 DMGs originating from the SARS-CoV-2 *in vitro* stimulated PBMCs
279 compared to non-stimulated PBMCs. Pathways with a nominal p-value < 0.05 were considered
280 significant.

281 **Comparisons between *in vivo* and *in vitro* setting as well as network analyses reveal**
282 **overlaps to SARS-CoV-2 interactome**

283 As similar pathways were revealed in the findings from the clinical study and the SARS-CoV-
284 2 stimulations, we wanted to explore further similarities in DNAm between the *in vivo* and *in*
285 *vitro* settings. Analyses of the overlap of shared DMGs identified in the two comparisons
286 revealed eight overlapping DMGs (*OR12D3*, *PCSK6*, *INPP5A*, *RAD51B*, *CDH4*, *PHACTR3*,
287 *CDH13*, *SFTA2*), of which one (*PCSK6*) was identified as directly interacting with SARS-
288 CoV-2. Additionally, to understand the biological context of the genes identified in the *in vitro*
289 comparison, we performed network analyses in the same manner as for the *in vivo*
290 comparison. These analyses found a module consisting of six genes (*TP53*, *INS*, *HSPA4*,
291 *SP1*, *ESR1* and *FAS*), which were among the previously identified module genes from the *in*
292 *vivo* setting and also were identical to those that had been identified by more than two
293 module identification methods (Figure 4A). Furthermore, explorations of the overlap between
294 identified genes in the differential DNAm analyses and network module analyses to the
295 genes from the SARS-CoV-2 interactome identified numerous interactions in the *in vivo*
296 (n=11/54), *in vitro* (n=100/542) and network module setting (n=33/66) (Figure S3).

297

298

299

300

301

302

303 **DISCUSSION**

304 The epigenetic events triggered during a mild COVID-19 infection are largely unknown,
305 despite the fact that these individuals make up a majority of all SARS-CoV-2-infected
306 individuals. In this study, we observed changes in the DNA methylome of PBMCs from
307 CC19s compared to non-infected individuals. A number of recent studies have studied
308 DNAm patterns in severely ill patients with COVID-19, mainly reflecting the acute phase of
309 the immune response. For instance, genes involved in antiviral responses driven by
310 interferons were shown to be transcriptionally inhibited by hypermethylation, in severely ill
311 COVID-19 patients compared to controls, while genes originating from inflammatory
312 responses were granted transcriptional accessibility through general hypomethylation (17).
313 Other studies reported on DNAm patterns in whole blood of COVID-19 sufferers, comparing
314 hospitalised severely ill individuals to mildly ill and healthy individuals (18), pre-pandemic
315 controls (19) and asymptomatic individuals (20), yet again showing mainly engagement of
316 several antiviral immunity-related pathways. Whether the changes we found are reflecting an
317 antiviral defence mechanism or reflect viral manipulation of the host epigenome warrants
318 further studies.

319 The main finding of our study was that a number of genes in the networks deriving from both
320 the DNA methylomes of mildly ill COVID-19 subjects and the *in vitro* stimulated PBMCs
321 methylomes were shared and consistently found by several module identification methods.
322 This may indicate the importance of these genes as hubs for protein-protein interactions in
323 the course of SARS-CoV-2 infection and recovery. One of these genes was tumor protein 53
324 (TP53), an evolutionarily conserved protein that is one of the most well-studied hub genes in

325 cell signalling due to its central role in cancer (21) and that interacts with a variety of viral
326 proteins from different classes (<https://thebiogrid.org>)(22). The ability of mutual inhibition and
327 downregulation has been shown for TP53 and one of the previously identified SARS
328 coronaviruses – SARS-CoV (23). Furthermore, TP53 has in several other studies been
329 identified as a hub gene, in whole blood from COVID-19 patients (24), and interacting with
330 ACE2 in SARS-CoV-2-infected human induced pluripotent stem cell-derived cardiomyocytes
331 (25). In line with findings from our study, transcriptomic analyses of PBMCs from a small
332 group of patients infected with SARS-CoV-2 revealed involvement of apoptosis and p53
333 signalling pathways (26). The relevance of this is supported by studies of the SARS-CoV-2
334 interactome, where TP53 was identified as a central player in apoptosis-mediated pathways
335 (27). In terms of apoptosis, the module gene Fas cell surface death receptor, FAS, is also
336 highly relevant. Higher expression of FAS on CD4+ T cells have been shown to correlate
337 with lower cell counts in Covid-19 patients (28). Along the same lines, elevated circulating
338 levels of the soluble form of FAS have recently been suggested to be causally contributing to
339 the severity of Covid-19, and may in turn originate from genetic splice variants (29).
340 Furthermore, apoptosis of T cells in PBMCs induced by FAS was reported to be increased in
341 Covid-19 patients (30), which along with the involvement of TP53 could explain the
342 lymphopenia frequently observed in COVID-19 subjects.

343 Interestingly, reports on differentially expressed genes overlapping between acute respiratory
344 distress syndrome and venous thromboembolism datasets identified both TP53 and
345 HSP90AA1, one of our other identified central genes, among the top ranked hub genes in
346 their networks (31). HSP90AA1 was furthermore shown to be upregulated in bronchial cells
347 of patients with mild COVID-19 disease, as compared to those with a severe disease course
348 (32), suggesting that this gene may be of particular importance in the mounting of a
349 protective antiviral response. Another heat shock protein in the network derived from our *in*
350 *vivo* and *in vitro* data, HSPA4, directly interacts with the SARS-CoV-2 M and N proteins and
351 also three of the virus' non-structural proteins (<https://thebiogrid.org>)(22). In fact, this heat

352 shock protein, a member of the HSP70 family, also binds proteins of the Human Herpes
353 Virus 4 and HIV. Although our study does not provide any evidence for a protective role,
354 HSP70 family members have been discussed as antiviral defence components (33, 34). In
355 addition, HSP70 members have been suggested as drug targets in viral infections, including
356 SARS-CoV-2 (35). Another interesting hub gene was *CFTR*, for which there is evidence for
357 correlations of the inactivating delta F508 polymorphism, which is protective against chloride
358 ion secreting diarrhoeas, with prevalence and mortality in Covid-19 (36). This is particularly
359 interesting as SARS-CoV-2-induced diarrhoea has been suggested to involve Ca²⁺ activated
360 chloride channels (37). Similarly, it has been hypothesised that transport of chloride ions over
361 CFTR may be implicated in Covid-19-induced lung oedema (38). Furthermore, the
362 muscarinic acetylcholine receptor 1 and 3 signalling pathway was present in over-
363 representation analyses of genes from the network analyses as well as the *in vitro*
364 stimulations. In post-viral fatigue patients, including post-SARS-CoV and myalgic
365 encephalomyelitis/chronic fatigue syndrome patients, this signalling pathway is dysfunctional
366 due to the development of anti-muscarinic receptor autoantibodies (39, 40). Although this
367 was not investigated in our study, this could suggest that these pathways found may be
368 implicated in the development of for instance post-acute COVID-19 syndrome, as the effects
369 we observe may have persisted for months after the initial exposure to the virus. Altogether,
370 the network centrality of the hub genes that we derived from the *in vivo* and *in vitro* data
371 suggests that they may be of particular importance in the interaction with epigenetically
372 modulated genes upon SARS-CoV-2 infection. Nevertheless, further studies are needed to
373 elucidate the mechanistic role of these genes during infection and recovery from COVID-19.

374 Although an obvious limitation of the study is the lack of validation of the DNAm findings on a
375 transcriptional level, it serves as a pilot study that generates hypotheses for further studies
376 within the field. Hence, whether the observed DNAm patterns are indeed associated or even
377 causally linked to host protective or host detrimental immune responses still needs to be
378 addressed in future studies. With more well-designed, larger, consecutive sample materials,

379 possibly also in closer proximity to the time of infection with SARS-CoV-2, it will be possible
380 to study the role of DNAm alterations in anti-viral defence and in viral manipulation of the
381 same.

382 An advantage of the investigation of epigenetic modifications in in mild to moderately ill
383 patients, is that we may be able to discern DNAm differences that otherwise would have
384 been masked due to an overriding inflammatory response. These subtle changes may not
385 only be relevant to how a less severe immune response is mounted towards SARS-CoV-2,
386 but also in the case of long-COVID-19. The presentation of longstanding symptoms could be
387 caused by detrimentally changed DNAm patterns, originally triggered as a short-term anti-
388 viral response. This should be explored in detail in further studies since the risk is that these
389 short-term responses may permanently alter and erroneously manifest in the DNA
390 methylome.

391 **CONCLUSIONS**

392 In conclusion, we found epigenome-wide differences in DNAm patterns of individuals that
393 had recovered from a mild-to-moderate disease course of COVID-19 compared to non-
394 infected controls. The DNAm changes observed during *in vivo* and *in vitro* exposure to
395 SARS-CoV-2 were translated to pathways of central relevance to COVID-19 through network
396 analyses. The study suggests that DNAm is one of several epigenetic mechanisms that are
397 altered upon SARS-CoV-2 infection. However, whether the effects are reflecting targeted
398 viral hijacking to evade host defence or host-protective antiviral defence mechanisms
399 remains to be determined.

400

401

402

403

404

405

406

407

408

409

410

411 **METHODS**

412 **Study population**

413 In this study, participants were enrolled between May 29th and July 10th 2020 during the first
414 wave of the SARS-CoV-2 pandemic in Linköping, Sweden. Individuals who had recovered
415 from and individuals who had not experienced COVID-19 were recruited after
416 announcements with leaflets. Exclusion criteria were the existence of current active SARS-
417 CoV-2 infection and/or other infectious disease symptoms, as well as being younger than 18
418 years. The study participants voluntarily entered the study in a consecutive manner. The
419 study was conducted on blood and saliva samples from in total 38 individuals from three
420 different groups; non-infected controls (Con, n=18), COVID-19 convalescents (CC19, n=14)
421 and symptom-free individuals with SARS-CoV-2-specific T cell responses (SFT, n=6).
422 Additionally, blood samples from anonymous healthy blood donors from the blood bank at
423 Linköping University Hospital before 2020 were included as a separate group in the analyses
424 (pre20, n=5), collected between 2014-2019 prior to the outbreak of the pandemic. CC19
425 participants presented with either mild or asymptomatic initial infection, and none was
426 admitted to hospital. Cons were defined as neither having any positive circulating IgG-
427 antibody or T cell responses to SARS-CoV-2, while CC19s were defined by the presence of
428 SARS-CoV-2-specific IgG antibodies in plasma using suspension multiplex immunoassay

429 (SMIA), some of which were positive for IgG in saliva, rapid test and in T cell responses as
430 well. From the included individuals, the following information was retrieved using health
431 questionnaires: self-reported COVID-19 symptoms (if applicable, one or several of the
432 following: fever, headache, shortness of breath, loss of smell/taste, cough, fatigue, muscle
433 pain, nausea, sinusitis/congestion), date of self-reported symptoms, weeks between
434 symptoms and sampling, age, sex, smoking, weight, height, comorbidities as well as
435 medications. The blood and saliva from the study participants was processed in a Biosafety
436 level-2 facility. For samples from the natural exposure cohort, all participants provided written
437 informed consent, and the present study was approved by the Regional Ethics Committee for
438 Human Research in Linköping (Dnr. 2019-0618). Regarding the anonymous blood samples
439 used for *in vitro* experiments, informed consent was given by the healthy donors at the time
440 of blood donation and the use of the donated blood for research purposes was guaranteed
441 as per the guidelines of Regional Ethics Committee for Human Research in Linköping and
442 the Helsinki Declaration.

443

444 **PBMC and plasma isolation from whole blood**

445 Peripheral blood was collected in three 10 ml EDTA tubes (BD Vacutainer, 10331254, Fisher
446 Scientific, Sweden). Up to 20 ml of whole blood was used for PBMC isolation after Ficoll-
447 Paque Plus gradient centrifugation (GE17-1440-03, GE Healthcare Life Sciences, Sigma-
448 Aldrich, Sweden) with SepMate™ tubes (85450, StemCell technologies, France) according
449 to the manufacturer's protocol. Cells were frozen in 10% DMSO (10103483, Fischer
450 Scientific, Sweden) in fetal bovine serum (FBS) (10270106, Gibco, Fischer Scientific,
451 Sweden) and kept at -150°C until analysis. After thawing, the cells were washed twice in cell
452 culture medium (RPMI medium 1640, 31870-025, 10% fetal bovine serum, 1%
453 penicillin/streptomycin, 15140, 1% L-glutamine, 25030081, all from Gibco, Fischer Scientific,
454 Sweden) further on termed as complete culture medium, prior to further processing. Up to 10

455 ml of whole blood was used for plasma separation by centrifugation (2000g for 15min, 4°C)
456 and aliquots were stored at -80°C till further analysis.

457

458 **Measurements of SARS-CoV-2-specific T cell responses using ELISpot**

459 Peptides for the spike (S) protein of SARS-CoV-2 were obtained from Mabtech (3629-1,
460 Sweden) and were reconstituted with di-methyl-sulphoxide (DMSO) at a concentration of 200
461 µg/ml according to the manufacturer's instructions. The SARS-CoV-2 S1 scanning pool
462 contains 166 peptides consisting of 15-mers, overlapping with 11 amino acids, covering the
463 S1 domain of the spike S1 protein (amino acid 13-685). The peptides were combined into
464 one pool. IFN-γ ELISpot Plus kit was purchased from Mabtech (3420-4HST-10, Sweden).
465 Briefly, the pre-coated wells were plated with unfractionated PBMCs at counts of 300 000
466 cells/well, and the cells were cultured with peptides for the S protein of SARS-CoV-2 at a
467 final concentration of 2 µg/ml (diluted in complete culture medium) for 20 to 22 hrs in a 37°C,
468 5% CO₂ incubator. Cells cultured with medium alone were used as negative controls.
469 Stimulation with anti-CD3 antibody at a concentration of 1 µg/ml was used as a positive
470 control for each subject. Anti-CD28 antibody (3608-1-50, Mabtech, Sweden) was included at
471 a final concentration of 0.1 µg/ml as a co-stimulator. All experiments were conducted in
472 duplicates and results represent the mean of the duplicates. The plates were then processed
473 according to the manufacturer's protocol. Estimation of specific T cell numbers was
474 expressed as spot-forming cells per 1x10⁶ PBMCs (SFC). SFC were counted using an
475 automated reading system (BioSys Bioreader 5000 Pro-F beta, Bio-sys GmbH, Germany)
476 and assessed with the Bioreader 5000 analyser. A stimulation index was calculated by
477 dividing the SFC elicited by a SARS-CoV-2 stimulus by the SFC present in the negative
478 control wells. An increment value was calculated by subtracting the SFC from the negative
479 control wells from the SFC of the stimulated wells. A stimulus was considered to be positive
480 when the stimulation index was >2, and the increment value was >10.

481

482 **Saliva samples**

483 Prior to saliva collection, participants were required to rinse their mouth with water and
484 confirmed they did not show documented oral disease or injury, that they had fasted,
485 refrained from smoking, chewing a gum, taking oral medication, tooth brushing for a
486 minimum of 1 hour before sampling and that no dental work had been performed within 24
487 hours prior to sample collection. Donors were asked to provide a 5 ml sample of saliva in a
488 50 ml sterile conical tube by passive drooling.

489 All saliva samples were stored/transported on ice upon receipt of the laboratory for
490 processing to preserve sample integrity. Samples were centrifuged (2500g for 20 minutes at
491 4°C) to pellet cells and insoluble matter. The supernatant was collected and samples were
492 complemented with cOmplete™ protease (#11836170001, Sigma) and Pierce™
493 phosphatase inhibitor cocktails (#88667, Thermo Scientific), aliquoted and frozen/stored at -
494 80°C on the same day. On the day of the assay, samples were thawed and micro-centrifuged
495 (2500g for 10 minutes at 4°C) prior to analysis.

496 **Antibody responses in plasma and saliva using Suspension Multiplex Immunoassay** 497 **(SMIA)**

498 MagPlex-C microspheres (Luminex Corp., Austin, TX, USA) were used for the coupling of
499 antigens according to the manufacturer's protocol as previously described (41). Briefly, 200
500 µl of the stock microsphere solution (1.25×10^7 beads/ml) were coupled by adding 10 µg of
501 recombinant SARS-CoV-2 Spike protein RBD His-Tag (#40592-V08B, SinoBiological Inc.,
502 USA). After the coupling, beads were incubated in phosphate buffered saline (PBS: 0.15 M
503 sodium chloride, 10 mM sodium phosphate, pH 7.4) containing 0.05% (v/v) Tween 20 (PBS-
504 T) for 15 min on a rocking shaker at RT. The beads were then washed with 0.5 ml
505 StabilGuard solution (SurModics, Eden Prairie, MN, USA, #SG01-1000) using a magnetic
506 separator (Milliplex® MAG handheld magnetic separation block for 96-well plates, Millipore

507 Corp. Missouri, USA. Cat. #40-285) and resuspended in 400 µl of StabilGuard solution. The
508 coupled beads were stored at 4°C in the dark until further use.

509 For plasma samples, 50 µl of plasma diluted 1:1000, and for saliva samples 50 µl of sample
510 diluted 1:2 in PBS-T containing and 1% (v/v) BSA (Sigma-Aldrich Sweden AB, Stockholm,
511 Sweden, #Sigma-Aldrich-SRE0036) (PBS-T + 1% BSA) was added per well of a flat bottom,
512 96-well µClear non-binding microtiter plate (Greiner Bio-One GmbH, Frickenhausen,
513 Germany, #Greiner-655906). Fifty microliters of a vortexed and sonicated antigen-coupled
514 bead mixture suspended in PBS-T + 1% BSA (~50 beads/µl) was then added to each well.
515 The plate was incubated in the dark at 600 rpm for 1h at RT. The wells were then washed
516 twice with 100 µl of PBS using a magnetic plate separator. The beads were resuspended in
517 100 µl of 1 µg/ml goat anti-human IgG-PE labelled antibody (Southern BioTech,,
518 Birmingham, AL, USA. Cat. #2040-09) in PBS-T + 1% BSA and incubated for 30 min at RT in
519 the dark with rotation at 600 rpm. The beads were subsequently washed twice with PBS,
520 resuspended in 100 µl of PBS and analysed in a FlexMap 3D® instrument (Luminex
521 Corporation, Austin, TX, USA) according to the manufacturer's instructions. A minimum of
522 100 events for each bead number was set to read and the median value was obtained for the
523 analysis of the data. All sample analyses were repeated three times. A naked, non-antigen-
524 coupled bead was included as a blank along with PBS-T + 1% BSA as a negative control.

525

526 **Rapid test for SARS-CoV-2-specific IgG antibodies**

527 SARS-CoV-2-specific antibody levels were validated using the Wondfo SARS-CoV-2
528 antibody test (lateral flow method) (Cat. # W195, Guangzhou, China) for rapid antibody
529 testing. 10 µl of blood was added to the sample well and 80 µl of buffer solution in the buffer
530 well, provided in the box by the manufacturer. The results were recorded as positive or
531 negative based on band appearance according to the instructions by the manufacturer.

532

533 ***In vitro* stimulation with SARS-CoV-2**

534 PBMC samples from four healthy blood donors, frozen in 2019 in -150 °C in foetal bovine
535 serum (FBS) with 10% DMSO, were thawed and added to 10 ml of Gibco Dulbecco's
536 Modified Eagle Medium (DMEM) (Thermo Fisher Scientific, Waltham, US) containing 1% L-
537 glutamine (Cat no: 25030-024, Gibco, Waltham, Massachusetts, USA), 1% penicillin-
538 streptomycin (Cat no: 15140148 Gibco) and 10% normal human serum (NHS) (pooled from 5
539 donors) filtered through a 40 µm strainer and pre-heated to 37 °C. The cells were washed
540 two times by centrifugation at 330g for 10 min. The pellet was resuspended in 1.5 ml medium
541 and 2 million per donor were seeded in six-well plates and incubated for 16-24 h. The cell
542 culture media were collected, and centrifugated at 330g for 5 min to pellet the non-adherent
543 cells.

544 For *in vitro* infection experiments, SARS-CoV-2 virus previously isolated in a Biosafety level
545 3 lab according to local safety regulations from the nasopharyngeal aspirate of a COVID-19
546 patient (early April 2020) was used (42). The isolated virus was passaged five times in Vero
547 E6 cells and for cell infection experiments, freeze-thawed medium supernatants of 4-5 days
548 infected cells or mock supernatants were used. Virus titers were determined using
549 immunoperoxidase assay. In brief, two-day old confluent cells (in a 96-well plate) were first
550 washed with Dulbecco's Modified Eagle's Medium (DMEM) (Gibco, Code: 13345364)
551 containing 100 µg/ml gentamicin, and 100 µl of 10-fold serially diluted SARS-CoV-2 virus
552 lysate was added in quadruplicate. SARS-CoV-2 or mock Vero cell supernatant was added
553 to the PBMC cultures corresponding to a multiplicity of infection of 0.01. 2 hours post
554 infection the cells were washed twice with DMEM and 100 µl of fresh DMEM (containing 2%
555 FBS and 100 µg/ml gentamicin) was added, and the plate was incubated for 8 hours at 37°C
556 in presence of 5% CO₂. After incubation, the supernatant was discarded, and the cells were
557 fixed for 2 hours with 4% formaldehyde. Next, Triton-X (1:500 in phosphate buffered saline,
558 PBS) was added for 15 min, washed once with PBS and incubated for 2 hours at 37°C with
559 PBS containing 3% BSA. Next, the cells were incubated with mouse-anti-dsRNA antibody

560 (Scions, Code: J2 at 1:100 dilution) for 1.5 h followed by detection using horseradish
561 peroxidase–conjugated goat anti-mouse IgG (heavy plus light chain) (Catalog: 1706516, Bio-
562 Rad Laboratories, Hercules, CA, USA) (1:1000) for 1 h. The plates were washed five times
563 with PBS between every incubation, all incubations were done at room temperature and the
564 antibody dilutions were made in PBS containing 1% BSA. Finally, the SARS CoV-2 infected
565 Vero E6 cells were identified using 3-aminoethylcarbazole (AEC) substrate. The spots
566 representing virus-infected cells were counted under the light microscope and the virus
567 lysate was titrated to be 5×10^6 per ml.

568 Cells were monitored in the IncuCyte S3 live cell analysis system (Sartorius, Göttingen,
569 Germany) to allow quantification of cell death in SARS-CoV-2 infected wells versus controls.
570 After 48h incubation the cell culture media was collected from each well and centrifugated at
571 330g for 5 min to collect the non-adherent cells. Lysis buffer (RLT from the AllPrep®
572 DNA/RNA Mini Kit, Qiagen, Hilden, Germany) was added to the wells to lyse adherent cells
573 and the mixture was then added to the pelleted non-adherent cells in order to collect DNA
574 (according to the manufacturer's instructions) from the entire PBMC fraction.

575

576 **Epigenome-wide DNA methylation analyses**

577 **DNA extraction and quantification**

578 For the performance of epigenome-wide DNA methylation analyses, DNA was extracted from
579 the above isolated PBMCs (approximately 2×10^6 cells) using the AllPrep® DNA/RNA Mini Kit
580 (Cat no: 80204, Qiagen, Hilden, Germany) according to the manufacturer's instructions.
581 Concentrations of extracted DNA were measured using the Qubit® 4.0 Fluorometer (Thermo
582 Fisher Scientific, Waltham, Massachusetts, U.S), using dsDNA High Sensitivity (HS) Assay
583 Kit and RNA HS Assay Kit. The measurement was performed according to the
584 manufacturer's instructions.

585

586 **Illumina MethylationEPIC 850K array**

587 DNA samples were sent to the Bioinformatics and Expression analysis Core facility,
588 Karolinska Institutet, Stockholm, Sweden, where the samples first went through bisulphite
589 conversion on site, followed by the performance of the Illumina Infinium MethylationEPIC
590 850K array. 200 ng of DNA from each sample was analysed.

591

592 **Statistics**

593 **Descriptive analyses on demographic variables**

594 Initial descriptive analyses of demographic variables were performed on the available
595 information about age, gender, smoking and BMI (kg/m²). Continuous variables were
596 compared using an unpaired two-tailed t-test and categorical variables were examined using
597 the Pearson χ^2 test or Fisher's exact test (if the number of observations was smaller than
598 five), see Table S1.

599 **DNA methylation analyses**

600 The resulting raw IDAT-files from the MethylationEPIC array analyses were processed in R
601 programming environment (version 4.0.2). The analyses were identically performed for the
602 clinical *in vivo* cohort and the *in vitro* experiment, unless stated otherwise.

603 **Pre-processing and quality control *in vivo***

604 The resulting raw IDAT-files containing the raw DNA methylation profiles for each cell type
605 were analysed in R (version 4.0.2) using the minfi package(43) (version 1.36.0) and the data
606 were pre-processed in several steps. The following filters were applied: i) removal of probes
607 with detection p-values above 0.01, ii) removal of non-CpG probes, iii) removal of multi-hit
608 probes, iv) removal of all probes in X and Y chromosomes. We removed the sex
609 chromosomes from our data set, as female X-inactivation skews the distribution of beta
610 values (Figure S4). Of the initial 865 918 probes, 841 524 probes remained upon filtering.

611 After filtering, quality control was performed, and normalisation of the data was done with
612 subset-quantile within array (SWAN) normalisation method (44). The β -values and M-values
613 of the samples were calculated against each probe per sample. The quality of the data was
614 assessed before and after the normalisation (Figure S5). Thereafter, we performed singular
615 value decomposition (SVD) analyses using the ChAMP package (45) (version 2.19.3) to
616 identify underlying components of variation within the filtered and normalised data set (Figure
617 S6). Significant components consisted of slide, batch and sample groups that contributed to
618 variation within the data set. Corrections were performed for the identified components using
619 ComBat from the SVA package (46) (version 3.38.0). As PBMCs consist of multiple
620 nucleated cell types in peripheral blood, we utilised the Houseman method to infer cell type
621 proportions within the samples (47). No differences could be determined in cell type
622 proportions between any of the individuals or between sample groups (Table S7), motivating
623 our choice of not correcting for these cell type proportions.

624

625 **Differential DNA methylation analysis *in vivo***

626 As we were interested in studying CpGs that were differentially methylated between CC19s
627 and non-infected controls from both before and after the start of the COVID-19 pandemic, we
628 performed differential DNA methylation analyses, using the limma package (version 3.46.0).
629 A linear model was fitted to the filtered, normalised and SVD-corrected DNA methylation
630 data. Identified sources of variation that were still present upon SVD correction provided the
631 basis for the inclusion of these variables as co-variates in the models, in this case gender
632 and BMI (Figure S6). For each investigated probe, moderated t-statistics, log₂ Fold Change
633 (logFC) and p-values were computed. The logFC values represent the average beta
634 methylation difference (from hereon referred to as mean methylation difference, MMD)
635 between the CC19s vs. non-infected controls (Cons + Pre20). Differentially methylated CpGs
636 (DMCs) were defined as CpG sites having a nominal p-value of less than 0.01 along with an
637 MMD of > 0.2. As a means to ascertain the quality of the identified DMCs, genomic inflation

638 and pertaining bias were estimated using the BACON package (version 1.18.0). As the
639 estimated genomic inflation for the comparison was close to 1 (genomic inflation: 1.20, bias:
640 0.01, Figure S7), this suggested that no major genomic inflation was present in the
641 comparisons, and no correction for this was deemed necessary. The distribution of the
642 DMCs among all investigated DNA methylation sites were illustrated by creating volcano
643 plots (EnhancedVolcano, version 1.8.0). Thereafter, the DMCs were mapped to their
644 corresponding DMGs. DMGs contained at least one DMC, and were considered hyper- or
645 hypomethylated if all DMCs within the gene were hyper- or hypomethylated, respectively. If
646 both hyper- and hypomethylated genes were present in the same gene, the gene was
647 considered having a mixed methylation pattern.

648 **Pre-processing and quality control *in vitro***

649 The resulting raw IDAT-files containing the raw DNA methylation profiles for each cell type
650 were analysed in R (version 4.0.2) using the minfi package (43) (version 1.36.0) and the data
651 were pre-processed in several steps. The following filters were applied: i) removal of probes
652 with detection p-values above 0.01, ii) removal of non-CpG probes, iii) removal of multi-hit
653 probes, iv) removal of all probes in X and Y chromosomes. In this dataset, we did not have
654 any information on demographic variables, as the samples derived from anonymous donors.
655 However, we still removed the sex chromosomes from our data set, as female X-inactivation
656 skews the distribution of beta values. Of the initial 861 728 probes, 837 694 probes remained
657 upon filtering. After filtering, quality control was performed, and normalisation of the data was
658 done with subset-quantile within array (SWAN) normalisation method (44). The Houseman
659 method was utilised to infer cell type proportions within the samples (47), yet again revealing
660 no differences could be determined in cell type proportions between any of the individuals
661 (Table S7), motivating our choice of not correcting for these cell type proportions. The β -
662 values and M-values of the samples were calculated against each probe per sample. The
663 quality of the data was assessed before and after the normalisation (Figure S8). SVA

664 package (version 3.40) was applied to correct the batch effect. Cell deconvolution was
665 performed using FlowSorted.Blood.EPIC package (version 1.11).

666

667 **Differential DNA methylation *in vitro***

668 To evaluate the difference between the MOCK and INFECTION, the fold change was
669 calculated using the cut-off obtained from the density plot (M-value $>|2|$; Figure S9) for each
670 CpG site. Only those CpGs with higher values than the cut-off, were selected for further
671 analysis. Venn analysis was performed among the samples using the ggVennDiagram
672 (version 1.1) package in R (version 4.0.3) and bioconductor (version 3.12).

673 **Pathway over-representation analyses**

674 To make biological sense of the putatively SARS-CoV-2-induced DNA methylation
675 differences, we performed PANTHER pathway over-representation test analyses using the
676 PANTHER database (version 16.0). The Fisher's exact test was used for generation of
677 nominal p-values (significance level set to p-value of < 0.05), in case false discovery rate
678 correction was too stringent. The significantly enriched pathways were displayed in dot plots
679 generated in R using ggplot2 package (version 3.3.3).

680 **Network analyses**

681 A network analysis was conducted to generate further and wider biological insight about the
682 DMGs generated in the *in vivo* setting. An input object was constructed using the pre-2020
683 (Pre20, n=5) and post-2020 (Con, n=18) non-exposed controls and COVID-19 convalescents
684 (CC19, n=14), as a two-column data frame containing gene annotation and P-value of the
685 significant DMGs (n=54). The graph clustering algorithm MCODE (48) was used to identify
686 molecular complexes and create a large disease module, which was then fitted to a protein-
687 protein interaction network, and both were analysed and rendered in Cytoscape (version
688 3.8.0). High confidence interactions with a STRINGdb confidence value >0.7 were displayed

689 in the network. Centrality measurements of degree, betweenness and closeness were used
690 to expose the most central nodes in the network. Finally, a functional enrichment of the
691 genes present within the module was carried out using StringDB (49). In addition, the
692 inference of modules was performed with two other methods from the MODifieR package
693 (DIAMOnD and WGCNA)(50) to study whether it was possible to condense the module
694 genes to fewer genes of particular interest within the network, for both the *in vivo* and the *in*
695 *vitro* setting.

696

697 **Overlap to SARS-CoV-2 interactome**

698 A publicly available protein-protein interaction (PPI) network of SARS-COV-2 and human
699 genes curated by BioGRID (version 4.4.197) was downloaded from the Network Data
700 Exchange in Cytoscape (version 3.8.0). The DMGs from the *in vivo* and *in vitro* setting
701 alongside the gene list from the module generated by MCODE were overlapped onto the PPI
702 network to visualise their respective distributions.

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722 **LIST OF ABBREVIATIONS**

723 CC19 – convalescent COVID-19 individuals

724 Con – Control (uninfected pandemic)

725 COVID-19 – Coronavirus disease -19

726 DMC – differentially methylated CpG site

727 DMG – differentially methylated gene

728 DNAm – DNA methylation

729 MMD – mean methylation difference

730 PBMC – peripheral blood mononuclear cell

731 PC – principal component

732 PCA – principal component analysis

733 PPI – protein-protein interaction

- 734 Pre20 – Control (uninfected, pre-pandemic 2020)
- 735 SARS – severe acute respiratory syndrome
- 736 SARS-CoV-2 – severe acute respiratory syndrome corona virus 2
- 737 SFT – symptom-free individuals with T cell response
- 738 SMIA – suspension multiplex immunoassay

739

740

741

742

743 REFERENCES

- 744 1. Schmidl C, Delacher M, Huehn J, Feuerer M. Epigenetic mechanisms regulating T-cell
745 responses. *The Journal of allergy and clinical immunology*. 2018;142(3):728-43.
- 746 2. Mueller AL, McNamara MS, Sinclair DA. Why does COVID-19 disproportionately affect
747 older people? *Aging*. 2020;12(10):9959-81.
- 748 3. Martin EM, Fry RC. Environmental Influences on the Epigenome: Exposure-Associated
749 DNA Methylation in Human Populations. *Annual Review of Public Health*. 2018;39(1):1-
750 25.
- 751 4. Zhang L, Lu Q, Chang C. Epigenetics in Allergy and Autoimmunity. *Advances in*
752 *Experimental Medicine and Biology*. 2020;1253:3-55.
- 753 5. Jin J, Xu H, Wu R, Niu J, Li S. Aberrant DNA methylation profile of hepatitis B virus
754 infection. *Journal of Medical Virology*. 2019;91(1):81-92.
- 755 6. Zhang X, Justice AC, Hu Y, Wang Z, Zhao H, Wang G, et al. Epigenome-wide
756 differential DNA methylation between HIV-infected and uninfected individuals.
757 *Epigenetics*. 2016;11(10):750-60.
- 758 7. Oriol-Tordera B, Berdasco M, Llano A, Mothe B, Gálvez C, Martínez-Picado J, et al.
759 Methylation regulation of Antiviral host factors, Interferon Stimulated Genes (ISGs) and
760 T-cell responses associated with natural HIV control. *PLoS pathogens*. 2020;16(8).
- 761 8. Das J, Idh N, Pehrson I, Paues J, Lerm M. A DNA methylome biosignature in alveolar
762 macrophages from TB-exposed individuals predicts exposure to mycobacteria.
763 *MedRxiv : the preprint server for health sciences*. 2021.
- 764 9. Karlsson L, Das J, Nilsson M, Tyrén A, Pehrson I, Idh N, et al. A Differential DNA
765 Methylome Signature of Pulmonary Immune Cells from Individuals Converting to Latent
766 Tuberculosis Infection. *MedRxiv : the preprint server for health sciences*. 2021.
- 767 10. Pehrson I, Das J, Idh N, Karlsson L, Rylander H, Hård af Segerstad H, et al. DNA
768 methylomes derived from alveolar macrophages display distinct patterns in latent
769 tuberculosis - implication for interferon gamma release assay status determination.
770 2021.
- 771 11. Menachery VD, Schäfer A, Burnum-Johnson KE, Mitchell HD, Eisfeld AJ, Walters KB,
772 et al. MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering
773 the epigenetic landscape. *Proceedings of the National Academy of Sciences*.
774 2018;115(5).

- 775 12. Schäfer A, Baric R. Epigenetic Landscape during Coronavirus Infection. *Pathogens*.
776 2017;6(1):8.
- 777 13. Sen R, Garbati M, Bryant K, Lu Y. Epigenetic mechanisms influencing COVID-19.
778 *Genome*. 2021;99(999):1-14.
- 779 14. Chlamydas S, Papavassiliou AG, Piperi C. Epigenetic mechanisms regulating COVID-
780 19 infection. *Epigenetics*. 2020:1-8.
- 781 15. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus
782 Disease 2019 (COVID-19) Outbreak in China. *JAMA*. 2020;323(13):1239-42.
- 783 16. Li J, Huang DQ, Zou B, Yang H, Hui W, Rui F, et al. Epidemiology of COVID-19: A
784 systematic review and meta-analysis of clinical characteristics, risk factors, and
785 outcomes. *Journal of Medical Virology*. 2021;93(3):1449-58.
- 786 17. Corley MJ, Pang A, Dody K, Mudd PA, Patterson BK, Seethamraju H, et al.
787 Genome-wide DNA methylation profiling of peripheral blood reveals an epigenetic
788 signature associated with severe COVID-19. *Journal of Leukocyte Biology*. 2021.
- 789 18. Zhou S, Zhang J, Xu J, Zhang F, Li P, He Y, et al. An epigenome-wide DNA
790 methylation study of patients with COVID-19. *Annals of human genetics*. 2021.
- 791 19. Balnis J, Madrid A, Hogan KJ, Drake LA, Chieng HC, Tiwari A, et al. Blood DNA
792 methylation and COVID-19 outcomes. *Clinical epigenetics*. 2021;13(1):118.
- 793 20. Castro de Moura M, Davalos V, Planas-Serra L, Alvarez-Errico D, Arribas C, Ruiz M, et
794 al. Epigenome-wide association study of COVID-19 severity with respiratory failure.
795 *EBioMedicine*. 2021;66:103339.
- 796 21. Levine AJ. p53: 800 million years of evolution and 40 years of discovery. *Nature*
797 *reviews Cancer*. 2020;20(8):471-80.
- 798 22. Oughtred R, Rust J, Chang C, Breitkreutz B-JJ, Stark C, Willems A, et al. The BioGRID
799 database: A comprehensive biomedical resource of curated protein, genetic, and
800 chemical interactions. *Protein science : a publication of the Protein Society*.
801 2021;30(1):187-200.
- 802 23. Ma-Lauer Y, Carbajo-Lozoya J, Hein MY, Müller MA, Deng W, Lei J, et al. p53 down-
803 regulates SARS coronavirus replication and is targeted by the SARS-unique domain
804 and PLpro via E3 ubiquitin ligase RCHY1. *Proceedings of the National Academy of*
805 *Sciences of the United States of America*. 2016;113(35):201.
- 806 24. Vastrad B, Vastrad C, Tengli A. Identification of potential mRNA panels for severe
807 acute respiratory syndrome coronavirus 2 (COVID-19) diagnosis and treatment using
808 microarray dataset and bioinformatics methods. *3 Biotech*. 2020;10(10):422.
- 809 25. Wicik Z, Eyileten C, Jakubik D, Simões SNN, Martins DC, Pavão R, et al. ACE2
810 Interaction Networks in COVID-19: A Physiological Framework for Prediction of
811 Outcome in Patients with Cardiovascular Risk Factors. *Journal of clinical medicine*.
812 2020;9(11).
- 813 26. Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A, et al. Transcriptomic characteristics of
814 bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19
815 patients. *Emerging microbes & infections*. 2020;9(1):761-70.
- 816 27. Tiwari R, Mishra AR, Gupta A, Nayak D. Structural similarity-based prediction of host
817 factors associated with SARS-CoV-2 infection and pathogenesis. *Journal of*
818 *biomolecular structure & dynamics*. 2021:1-12.
- 819 28. Bellesi S, Metafuni E, Hohaus S, Maiolo E, Marchionni F, D'Innocenzo S, et al.
820 Increased CD95 (Fas) and PD-1 expression in peripheral blood T lymphocytes in
821 COVID-19 patients. *British journal of haematology*. 2020;191(2):207-11.
- 822 29. Klaric L, Gisby JS, Papadaki A, Muckian MD, Macdonald-Dunlop E, Zhao JH, et al.
823 Mendelian randomisation identifies alternative splicing of the FAS death receptor as a
824 mediator of severe COVID-19. *medRxiv : the preprint server for health sciences*. 2021.
- 825 30. Zhu L, Yang P, Zhao Y, Zhuang Z, Wang Z, Song R, et al. Single-Cell Sequencing of
826 Peripheral Mononuclear Cells Reveals Distinct Immune Response Landscapes of
827 COVID-19 and Influenza Patients. *Immunity*. 2020;53(3):685-696000.
- 828 31. Mishra A, Chanchal S, Ashraf MZ. Host-Viral Interactions Revealed among Shared
829 Transcriptomics Signatures of ARDS and Thrombosis: A Clue into COVID-19
830 Pathogenesis. *TH open : companion journal to thrombosis and haemostasis*. 2020;4(4).
- 831 32. Ma D, Liu S, Hu L, He Q, Shi W, Yan D, et al. Single-cell RNA sequencing identify
832 SDCBP in ACE2-positive bronchial epithelial cells negatively correlates with COVID-19
833 severity. *Journal of cellular and molecular medicine*. 2021.

- 834 33. Kim MY, Shu Y, Carsillo T, Zhang J, Yu L, Peterson C, et al. hsp70 and a novel axis of
835 type I interferon-dependent antiviral immunity in the measles virus-infected brain.
836 *Journal of virology*. 2013;87(2):998-1009.
- 837 34. Kim MY, Ma Y, Zhang Y, Li J, Shu Y, Oglesbee M. hsp70-dependent antiviral immunity
838 against cytopathic neuronal infection by vesicular stomatitis virus. *Journal of virology*.
839 2013;87(19):10668-78.
- 840 35. Tampere M, Pettke A, Salata C, Wallner O, Koolmeister T, Cazares-Körner A, et al.
841 Novel Broad-Spectrum Antiviral Inhibitors Targeting Host Factors Essential for
842 Replication of Pathogenic RNA Viruses. *Viruses*. 2020;12(12).
- 843 36. Delanghe JR, De Buyzere ML, Speeckaert MM. Genetic Polymorphisms in the Host
844 and COVID-19 Infection. *Advances in experimental medicine and biology*.
845 2021;1318:109-18.
- 846 37. Donowitz M, Tse C-MM, Dokladny K, Rawat M, Horwitz I, Ye C, et al. SARS-COV-2
847 induced Diarrhea is inflammatory, Ca²⁺ Dependent and involves activation of calcium
848 activated Cl channels. *bioRxiv : the preprint server for biology*. 2021.
- 849 38. Abdel Hameid R, Cormet-Boyaka E, Kuebler WM, Uddin M, Berdiev BK. SARS-CoV-2
850 may hijack GPCR signaling pathways to dysregulate lung ion and fluid transport.
851 *American journal of physiology Lung cellular and molecular physiology*. 2021;320(3).
- 852 39. Blomberg J, Gottfries C-GG, Elfaitouri A, Rizwan M, Rosén A. Infection Elicited
853 Autoimmunity and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: An
854 Explanatory Model. *Frontiers in immunology*. 2018;9:229.
- 855 40. Skiba MA, Kruse AC. Autoantibodies as Endogenous Modulators of GPCR Signaling.
856 *Trends in pharmacological sciences*. 2021;42(3):135-50.
- 857 41. Rizwan M, Rönnerberg B, Cistjakovs M, Lundkvist Å, Pipkorn R, Blomberg J. Serology in
858 the Digital Age: Using Long Synthetic Peptides Created from Nucleic Acid Sequences
859 as Antigens in Microarrays. *Microarrays*. 2016;5(3):22.
- 860 42. Nissen K, Hagbom M, Krambrich J, Akaberi D, Sharma S, Ling J, et al. Presymptomatic
861 viral shedding and infective ability of SARS-CoV-2; a case report. *Heliyon*. 2021;7(2).
- 862 43. Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, et al.
863 Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium
864 DNA methylation microarrays. *Bioinformatics (Oxford, England)*. 2014;30(10):1363-9.
- 865 44. Maksimovic J, Gordon L, Oshlack A. SWAN: Subset-quantile within array normalization
866 for illumina infinium HumanMethylation450 BeadChips. *Genome biology*. 2012;13(6).
- 867 45. Morris TJ, Butcher LM, Feber A, Teschendorff AE, Chakravarthy AR, Wojdacz TK, et al.
868 ChAMP: 450k Chip Analysis Methylation Pipeline. *Bioinformatics (Oxford, England)*.
869 2014;30(3):428-30.
- 870 46. Leek JT, Johnson EW, Parker HS, Jaffe AE, Storey JD. The sva package for removing
871 batch effects and other unwanted variation in high-throughput experiments.
872 *Bioinformatics*. 2012;28(6):882-3.
- 873 47. Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH,
874 et al. DNA methylation arrays as surrogate measures of cell mixture distribution. *BMC*
875 *bioinformatics*. 2012;13:86.
- 876 48. Bader GD, Hogue CW. An automated method for finding molecular complexes in large
877 protein interaction networks. *BMC bioinformatics*. 2003;4:2.
- 878 49. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING
879 v11: protein-protein association networks with increased coverage, supporting
880 functional discovery in genome-wide experimental datasets. *Nucleic acids research*.
881 2019;47(D1).
- 882 50. de Weerd HA, Badam TV, Martínez-Enguita D, Åkesson J, Muthas D, Gustafsson M,
883 et al. MODifieR: an ensemble R package for inference of disease modules from
884 transcriptomics networks. *Bioinformatics (Oxford, England)*. 2020;36(12):3918-9.

885

886

887

888

889

890

891

892

893

894

895

896

897

898 **DECLARATIONS**

899 *Ethics approval and consent to participate:*

900 All participants provided informed consent prior to inclusion in the study. Ethical permission
901 for this study has been granted by the Regional Ethics Committee for Human Research in
902 Linköping (Dnr. 2019-0618).

903 *Consent for application*

904 Not applicable

905 *Availability of data and materials*

906 The datasets used and/or analysed in the presented work will be available upon publication
907 due to a pending patent, for reference: GeneExpression Omnibus (GEO-ID: GSE178962).

908 *Competing interests*

909 None of the authors declare any competing interests.

910 *Funding*

911 This study was supported by grants from the Swedish Heart and Lung Foundation (M.L.:
912 20200319), the Swedish Research Council (A.R.: Covid-19/biobank 210202#1) and the
913 Open Medicine foundation (A.R.: OMF190626).

914 *Author's contributions*

915 M.L. and A.R. designed the study. A.R., E.A. and M.R. were responsible for sample
916 collection and performed the ELIspot and SMIA analyses. M.L., L.K and S.Sh. performed the
917 *in vitro* SARS-CoV-2 stimulation of PBMCs. L.K. prepared all PBMC samples for epigenome-
918 wide DNA methylation analyses. J.H. and J.D. provided guidance and expertise on the
919 performance of the statistical and bioinformatic analyses. S.Sa. has lead and performed the
920 majority of the statistical and bioinformatic analyses, with support from J.D., L.K., L.P. and
921 J.H. The findings were presented by J.H., S.Sa., L.K., J.D. and L.P. All authors interpreted
922 and discussed the results. J.H. drafted the manuscript. All authors contributed to and
923 approved the final draft for publication.

924 *Acknowledgements*

925 We would like to thank the Bioinformatics and Expression analysis Core facility at Karolinska
926 Institutet for their fruitful collaboration and the performance of the Illumina Infinium
927 MethylationEPIC 850K arrays described in this paper.

928 *Author's information (optional)*

929 Not applicable

930

931

932